A modified regimen of extracorporeal cardiac shock wave therapy for treatment of coronary artery disease

Table 2 Comparison of CCS, SAQ, 6MWT, nitroglycerin dosage, and NYHA classification

	Control group (14)	Group A ( n = 20)	Group B ( n = 21)	P
6MWT, meters
0 month	363.86 ± 150.92	344.25 ± 106.44	329.43 ± 134.71	0.617
3 month	322.07 ± 150.07	422.20 ± 77.30^§	385.43 ± 78.62^§	0.073
6 month	325.93 ± 157.32	434.25 ± 99.70^§	405.33 ± 104.36^§	0.296
12 month	348.43 ± 132.06	477.95 ± 105.34^a§	452.00 ± 117.47^a	0.020^*
CCS grading of angina
0 month	2 (2.0, 3.0)	2 (1, 2)	3 (2, 3)^b	0.045^*
3 month	2 (2.0, 2.3)	1 (1, 1)^a§	2 (1, 2)^§	<0.001^*
6 month	2 (1.0, 2.3)^§	1 (1, 1)^a§	2 (1, 2)^§	0.016^*
12 month	2 (1.0, 3.0)	1 (1, 1)^a§	1 (1, 2)^a§	<0.001^*
NYHA classification
0 month	2 (1, 3)	1.5 (1, 3)	2 (1, 2.5)	0.822
3 month	1 (1, 3)	1 (1, 2)^§	1 (1, 1)^§	0.138
6 month	1 (1, 2.3)	1 (1, 1)^§	1 (1, 1)^§	0.081
12 month	1 (1, 2.3)	1 (1, 1)^§	1 (1, 1)^a§	0.018^*
SAQ score
0 month	63.21 ± 11.89	64.90 ± 11.72	67.71 ± 13.05	0.549
3 month	63.86 ± 13.27	69.50 ± 10.28	76.38 ± 13.20^a§	0.015^*
6 month	60.14 ± 12.82	75.00 ± 10.45^a§	76.14 ± 12.28^a§	<0.001^*
12 month	59.21 ± 15.66	79.63 ± 9.87^a§	82.70 ± 10.16^a§	<0.001^*
Nitroglycerin (times/week)
0 month	1 (0, 4)	1 (0, 2)	2 (0, 3)	0.589
3 month	1 (0, 4)	0 (0, 1)	0 (0, 2)	0.151
6 month	0 (0, 2)	0 (0, 1)	0 (0, 1)	0.597
12 month^#	1 (0, 3)	0 (0, 0)^a	0 (0, 0)^a	0.023^*

Data were presented as mean ± standard deviation, number (%), or median (IRQ) as described in the statistical analysis methods.
^#One patient in group A and 11 patients in group B had missing data of nitroglycerin dosage at month 12.
*P < 0.05, indicates significant difference among control group, group A, and group B.
^a,b P < 0.0167 (0.05/3), indicates significant difference was identified when compared with ^acontrol group and ^bgroup A.
^§ P < 0.05, indicates significant difference was identified when compared with month 0 of the corresponding group.

ISSN: 1476-7120